Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 8/20 | 0.46 |
| ▸ | F2 | P00734 | 8/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13061977 | 1.00 | PSMB5 (0.46) | PSMB5F2PRSS1PREPPSEN1 | |
| SCHEMBL21356873 | 0.86 | PREP (0.48) | PSMB5F2PRSS1PREPPSEN1 | |
| SCHEMBL21365255 | 0.84 | PSMB5 (0.55) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL21365291 | 0.83 | PSMB5 (0.52) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL23656992 | 0.83 | PSMB5 (0.52) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL13061975 | 0.82 | PREP (0.44) | PSMB5F2PRSS1PREPPSEN1 | |
| SCHEMBL3776158 | 0.82 | PREP (0.44) | PSMB5F2PRSS1PREPPSEN1 | |
| SCHEMBL30321063 | 0.82 | PREP (0.44) | PSMB5F2PRSS1PREPPSEN1 | |
| SCHEMBL16284883 | 0.81 | EGFR (0.42) | PSMB5F2PRSS1PREPPSEN1 | |
| SCHEMBL22370670 | 0.81 | EGFR (0.42) | PSMB5F2PRSS1PREPPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| EP-3978488-A1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Universitetet I Oslo (NO) | 2022-04-06 | — | — | EP | disclosed |
| US-20210221791-A1 | COMPOUNDS | UNIVERSITETET I OSLO (NO) | 2021-07-22 | — | — | US | disclosed |
| EP-3497095-B1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | UNIV OSLO (NO) | 2021-07-14 | — | — | EP | disclosed |
| EP-3497095-B1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | UNIV OSLO (NO) | 2021-07-14 | — | — | EP | disclosed |
| US-10961223-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2021-03-30 | — | — | US | disclosed |
| US-20190284167-A1 | COMPOUNDS | UNIVERSITETET I OSLO (NO) | 2019-09-19 | — | — | US | disclosed |
| WO-2018033719-A1 | COMPOUNDS | UNIVERSITETET I OSLO (NO) | 2018-02-22 | — | — | WO | disclosed |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| EP-2220096-A1 | BETA-LACTAMASE INHIBITORS | Protez Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009064413-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | PSMB5 1165/4885F2 2849/4885PRSS1 1459/4885 |
| US-11649222-B2 | Compounds | SLC30A6, SLC39A11, SLC39A3 | PSMB5 811/4885F2 538/4885PRSS1 1954/4885 |
| US-10961223-B2 | Compounds | SLC30A6, SLC39A11, SLC30A5 | PSMB5 881/4885F2 543/4885PRSS1 1842/4885 |
| US-20190284167-A1 | COMPOUNDS | SLC30A6, SLC39A11, SLC30A5 | PSMB5 881/4885F2 543/4885PRSS1 1842/4885 |
| US-20210221791-A1 | COMPOUNDS | SLC30A6, SLC30A5, SLC39A11 | PSMB5 522/4885F2 554/4885PRSS1 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.